UBS Group’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

UBS Group’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,533	Closed	-$94K	–	8408
2016 Q3	$94K	Buy	4,533 +3,533	+353%	+$40.7K	﹤0.01%	5035
2016 Q2	$11K	Hold	1,000	–	–	﹤0.01%	6754
2016 Q1	$7K	Hold	1,000	–	–	﹤0.01%	6891
2015 Q4	$18K	Buy	+1,000	New	+$13.8K	﹤0.01%	6889
2015 Q3	–	Sell	-1,995	Closed	-$29K	–	8898
2015 Q2	$29K	Buy	+1,995	New	+$27.1K	﹤0.01%	6526
2015 Q1	–	Sell	-566	Closed	-$9K	–	9858
2014 Q4	$9K	Buy	+566	New	+$8.28K	﹤0.01%	8532

UBS Group's VTAE Position: Q4 2016 in Review

UBS Group sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 4,533 shares — an estimated $94K sold.

UBS Group first reported a position in VTAE in Q4 2014 and held it in 6 quarters. The position peaked at $94K in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

UBS Group reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
UBS Group sold 4,533 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $94K.
UBS Group first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2014 and held it in 6 quarters.
UBS Group's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $94K in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.